Story perspectives

Eli Lilly Stock Soars, Faces Price Cut Concerns

10/24/2025

38 9

Summary

Story summary

Eli Lilly's stock rose over 9% in early October 2025, reaching approximately $832 due to advancements in its weight-loss and Alzheimer’s drugs.
By October 23, shares traded near $818, marking a 6% year-to-date increase, in line with the S&P 500 health-care index.
Concerns emerged after President Trump announced plans to reduce prices for competing drugs, leading to a 4% drop in Lilly's shares.
The EU approved Lilly's Alzheimer’s antibody Kisunla, and the company partnered with Cipla to market its weight-loss drug in India.
Analysts generally maintain a bullish outlook on Lilly's future.

1 of 1

Story summary

Eli Lilly's stock rose over 9% in early October 2025, reaching approximately $832 due to advancements in its weight-loss and Alzheimer’s drugs.
By October 23, shares traded near $818, marking a 6% year-to-date increase, in line with the S&P 500 health-care index.
Concerns emerged after President Trump announced plans to reduce prices for competing drugs, leading to a 4% drop in Lilly's shares.
The EU approved Lilly's Alzheimer’s antibody Kisunla, and the company partnered with Cipla to market its weight-loss drug in India.
Analysts generally maintain a bullish outlook on Lilly's future.